News | February 23, 2015

PET/CT scans changed treatment in more than 28 percent of patients

PET/CT, lung cancer, follow-up, tumor tracking, nuclear imaging, trial

February 23, 2015 — New research from Johns Hopkins School of Medicine reveals a high value for scans which could lead to future change of reimbursement policies for follow-up positron emission tomography/computed tomography (PET/CT) studies in lung cancer. The study, featured in the February 2015 issue of The Journal of Nuclear Medicine, establishes the value of fourth and subsequent follow-up PET/CT scans in clinical assessment and management change in patients with the disease.

In the retrospective study, a total of 1,171 patients with biopsy-proven lung cancer who had positron emission tomography with a radioactive tracer (18F-FDG) were identified at a single tertiary center from 2001 to 2013. Among these, 85 patients (7.3 percent) had four or more follow-up PET/CT scans with a total of 285 fourth and subsequent follow-up PET/CT scans. Median follow-up from the fourth scan was 31.4 months. The follow-up PET/CT scan results were correlated with clinical assessment and treatment changes.

Of the 285 fourth and subsequent follow-up PET/CT scans, 149 (52.28 percent) were interpreted as positive and 136 (47.7 percent) were interpreted as negative for recurrence or metastasis. A total of 47 (55.3 percent) patients died during the study period. PET/CT identified recurrence or metastasis in 44.3 percent of scans performed without prior clinical suspicion and ruled out recurrence or metastasis in 24.2 percent of scans performed without prior clinical suspicion. The PET/CT scan resulted in treatment change in 28.1 percent (80/285) of the patients. New treatment was initiated in 20.4 percent (58/285) scan times, treatment was changed in 5.6 percent (16/285) scan times and ongoing treatment was stopped in 2.1 percent (6/285) scan times.

“Although the value of FDG PET/CT has been established in the follow-up of patients with lung cancer, this study specifically looks at the value of the fourth and subsequent follow-up PET/CT studies, which has not been addressed in any prior studies,” stated Rathan Subramaniam, M.D., Ph.D., lead author of the study. “We now need to establish similar evidence for other human solid tumors,” Subramaniam continued.  

The study was performed in the context of the recent Center for Medicaid and Medicare Services declaration that only three FDG PET/CT scans will be covered under section 1862(a)(1)(A) when used to guide subsequent management of anti-tumor treatment strategy after completion of initial anticancer therapy. Coverage of any additional FDG PET/CT scans will be determined by local Medicare administrative contractors. 

For more information: www.snmmi.org

Related Content

News | Magnetic Resonance Imaging (MRI)

December 1, 2021 — In the first MRI-based study to investigate prenatal alcohol exposure, researchers found significant ...

Time December 01, 2021
arrow
News | Coronavirus (COVID-19)

November 30, 2021 — COVID-19 of mild to moderate severity in pregnant women appears to have no effect on the brain of ...

Time November 30, 2021
arrow
News | Computed Tomography (CT)

November 30, 2021 — A three-year study of more than 1,000 patients found that the risk of delayed intracranial ...

Time November 30, 2021
arrow
News | Coronavirus (COVID-19)

November 29, 2021 — The largest multi-institutional international study to date on brain complications of COVID-19 has ...

Time November 29, 2021
arrow
News | Artificial Intelligence

November 28, 2021 — Riverain Technologies, a leader in artificial intelligence (AI) for early, efficient detection of ...

Time November 28, 2021
arrow
News | Coronavirus (COVID-19)

November 24, 2021 — Significant decreases in CT imaging for cancer persisted even after the peak of the COVID-19 ...

Time November 24, 2021
arrow
News | Lung Imaging

November 23, 2021 — Median Technologies announces new outstanding performance of its lung cancer screening (LCS) CADx1 ...

Time November 23, 2021
arrow
News | Magnetic Resonance Imaging (MRI)

November 23, 2021 — Researchers at Yale University analyzing specialized MRI exams found significant changes in the ...

Time November 23, 2021
arrow
News | Interventional Radiology

November 23, 2021 — A minimally invasive ablation procedure offers long-term relief for patients who experience chronic ...

Time November 23, 2021
arrow
News | Nuclear Imaging

November 22, 2021 — IBA, a leader in particle accelerator technology, and NorthStar Medical Radioisotopes LLC, a global ...

Time November 22, 2021
arrow
Subscribe Now